OBJECTIVE: To evaluate the long-term efficacy and duration of yeast-derived recombinant hepatitis B vaccine in hepatitis B virus (HBV)-endemic areas. METHOD: A cross-sectional investigation was carried out in five HBV-endemic areas. Children who were born between 1997 and 2008 and vaccinated with yeast-derived recombinant hepatitis B vaccine were selected. Serum samples were taken to test HBV infection markers by microparticle enzyme immunoassay, and the results were compared to those before vaccination. RESULTS: 7066 subjects were enrolled. The average adjusted hepatitis B surface antigen (HBsAg) prevalence was 1.02%. HBV core antibody (anti-HBc) prevalence was 3.54%. The overall percentage of HBsAg(-)&Anti-HBc(-)&Anti-HBs(+) was 61.34%. With time after immunization, the percentage annually decreases from 86.11% in 2008 to 49.80% in 1997. Geometric mean concentration (GMC) of anti-HBs decreased significantly annually. The portion of GMC=100-999.9 mIU/ml was 48.0% in 2008, and decreased to 16.7% in 1997. CONCLUSION: HBsAg prevalence decreased dramatically. This shows that the yeast-derived recombinant hepatitis B vaccine is effective and stable after being used for 12 years in HBV-endemic areas. It is not suggested to carry out booster immunization. Crown
OBJECTIVE: To evaluate the long-term efficacy and duration of yeast-derived recombinant hepatitis B vaccine in hepatitis B virus (HBV)-endemic areas. METHOD: A cross-sectional investigation was carried out in five HBV-endemic areas. Children who were born between 1997 and 2008 and vaccinated with yeast-derived recombinant hepatitis B vaccine were selected. Serum samples were taken to test HBV infection markers by microparticle enzyme immunoassay, and the results were compared to those before vaccination. RESULTS: 7066 subjects were enrolled. The average adjusted hepatitis B surface antigen (HBsAg) prevalence was 1.02%. HBV core antibody (anti-HBc) prevalence was 3.54%. The overall percentage of HBsAg(-)&Anti-HBc(-)&Anti-HBs(+) was 61.34%. With time after immunization, the percentage annually decreases from 86.11% in 2008 to 49.80% in 1997. Geometric mean concentration (GMC) of anti-HBs decreased significantly annually. The portion of GMC=100-999.9 mIU/ml was 48.0% in 2008, and decreased to 16.7% in 1997. CONCLUSION: HBsAg prevalence decreased dramatically. This shows that the yeast-derived recombinant hepatitis B vaccine is effective and stable after being used for 12 years in HBV-endemic areas. It is not suggested to carry out booster immunization. Crown
Authors: H Li; G J Li; Q Y Chen; Z L Fang; X Y Wang; C Tan; Q L Yang; F Z Wang; F Wang; S Zhang; S L Bi; L P Shen Journal: Epidemiol Infect Date: 2017-01-09 Impact factor: 4.434
Authors: Maimuna Mendy; Ingrid Peterson; Safayet Hossin; Tom Peto; Momodou L Jobarteh; Adam Jeng-Barry; Mamadi Sidibeh; Abdoulie Jatta; Sophie E Moore; Andrew J Hall; Hilton Whittle Journal: PLoS One Date: 2013-03-22 Impact factor: 3.240
Authors: Livia Melo Villar; Luciane Almeida Amado; Adilson José de Almeida; Vanessa Salete de Paula; Lia Laura Lewis-Ximenez; Elisabeth Lampe Journal: Biomed Res Int Date: 2014-07-01 Impact factor: 3.411